Description

Study Objective: To decipher the cellular composition of the bone marrow microenvironment before and after treatment with azacitidine and venetoclax. Objective 2: To functionally validate the cellular composition of the bone marrow environment and its contribution in response to treatment using an in vitro model. Objective 3: To evaluate the association between the cellular composition of the bone marrow environment and the achievement of clinical response. Objective 4: To investigate whether the cellular composition of the bone marrow environment and its contribution in response to treatment is associated with lower survival at 18 months. The primary endpoint will be the discovery of the mechanisms of the microenvironment of susceptibility to immunotherapy and their correlation with clinical response (achievement of CR or refractoriness) and survival data. More specifically:

1. Pan-tissue AHR signature - Pan-tissue AHR signature levels will be measured at T1 and T2 using iterative cycles of computational biology analysis and experimental validation. In particular, expression levels will be measured and a cut-off will be set for genes differentially expressed at log2 fold change;
2. The expression level of IFN-y in AML cells (% positive cells) and IDO1 in MSCs (mRNA levels mRNA levels) will be measured at T1 and T2. The expression of IDO1 will be measured in relation to the infiltration of Treg into the bone marrow. A cutoff for IFN-y and IDO1 expression will be set at 30% with fold-change>2 at T2 over T1;
3. The effects of IDO1 inhibitor on metabolic reactivation of effector T cells will be measured at T1 and T2 via mTOR activation. The following parameters will be measured in percentage: 1) glucose dependence, 2) mitochondrial dependence 3) glycolytic capacity and 4) fatty acid and AA oxidation capacity to determine the metabolic state. It will be evaluated the fold change between T2 and T1 of these 4 parameters; STUDY DESIGN This is a prospective, multicentre, tissue-based study aimed at collecting and characterising human tissues isolated from patients with acute myeloid leukaemia, who will receive azacitidine and venetoclax as the standard treatmentv as part of normal clinical practice. Specifically, in addition to the visits as part of normal clinical practice, samples of 80 mL of PB, 45 mL of BM and 1.5 mL of urine in addition to the scheduled blood samples. Samples will be collected at diagnosis (T1) and at the time of treatment response assessment = after the second cycle with azacitidine and venetoclax (T2). Treatment response will be assessed on the basis of the criteria standard response criteria for acute myeloid leukaemia according to the 2022 recommendations of a group of international experts on behalf of European LeukemiaNet25.Patients will be followed up for survival data. The source of survival data will be the patient's medical record. The study will include newly diagnosed, untreated adult patients with acute myeloid leukaemia who are not eligible for chemotherapy, candidates to receive the combination of venetoclax and azacitidine according to standard clinical practice and regardless of study participation. Patients will be enrolled at the time of disease diagnosis. For healthy donors, a total of a total of 60 buffy coats over 24 months. All patients who do not receive treatment (T2) will be excluded from the study. All 60 patients will be considered for the For objectives 2, 3 and 4, only patients who have completed both cycles of therapy will be considered. who have completed both cycles of therapy. The enrolment period of the subjects participating study subjects will be 18 months, the sample collection period will be 2 months, the clinical data analysis period will be 4 months, the clinical data analysis period will be 4 months, the follow-up period will be 12 months, for a total study duration of 36 months.

The study is funded by 'TRANSCAN-3 ERA-NET: supported collaboration of national national and regional programmes in cancer research'; Joint Transnational Call 2021 (JTC 2021) co-funded by the European Commission/DG Research and Innovation: 'Next generation cancer immunotherapy: Targeting the tumour microenvironment'.